BioNTech Investor Relations Material

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Additionaly its clinical development will target the treatment of infectious diseases, including prophylactic vaccine approach that includes mRNA. It is also developing various neoantigen-based immunotherapies in collaboration with Pfizer Inc.; other checkpoint molecules; and next-generation antigen receptor T-cell products. The company was formerly known as BioNtech Therapeutics GmbH. BioNTech SE was founded in 2008 and is headquartered in Mainz, Germany.